Bayer's Legal Clock Ticks as $7.25 Billion Settlement Faces Dual Challenges and Strong Business Holds the Line
26.05.2026 - 22:00:42 | boerse-global.de
The calendar is dictating Bayer’s near-term trajectory. A critical opt-out deadline for its $7.25 billion glyphosate settlement arrives on June 4, while the U.S. Supreme Court weighs a separate case that could reshape the entire Roundup litigation landscape. The stock, trading at €37.74 on Tuesday after a 1.95% slide, now sits 23.25% below its 52-week high of €49.17, and has slipped nearly 1% since the start of the year.
Two-front legal squeeze
The immediate pressure comes from a group of 13 Missouri plaintiffs’ attorneys, who have formally asked a court to block the proposed settlement. Their opposition threatens to unravel a deal that Bayer Chief Executive Bill Anderson has pegged as central to capping legal risks before year-end. The opt-out window slams shut on June 4, meaning plaintiffs must decide whether to join the class-wide accord or continue litigating individually. A final fairness hearing is scheduled for July.
Meanwhile, the U.S. Supreme Court is reviewing Durnell, a case that examines whether federal labeling regulations preempt state-level failure-to-warn claims. A ruling favorable to Bayer, expected by the end of July, could effectively close the door on tens of thousands of pending Roundup cases. Anderson has pledged to investors that the company will significantly reduce legal uncertainty in 2026, regardless of the Supreme Court outcome.
Operational momentum presses on
Away from the courtrooms, Bayer’s underlying business delivered a strong first quarter. Group EBITDA rose 9% to roughly €4.5 billion, while net profit doubled to €2.76 billion. The Crop Science division, buoyed by a 6.8% currency-adjusted revenue gain, outperformed expectations thanks to higher corn seed sales and a soybean licensing settlement. Lower production costs from ongoing efficiency programs also boosted margins.
Should investors sell immediately? Or is it worth buying Bayer?
The pharmaceuticals unit added its own catalyst. Sales of prostate cancer drug Nubeqa and kidney medicine Kerendia together jumped 64% in the first quarter. Bayer is now gearing up a new clinical collaboration to test Darolutamide (Nubeqa) in combination with OP-3136, a novel KAT6 inhibitor. The 36-patient study is expected to launch in the second half of 2026, aiming to expand Nubeqa’s addressable market.
Restructuring and debt reduction
The company’s “Dynamic Shared Ownership” (DSO) overhaul is accelerating. Bayer has already halved the number of management layers and cut two-thirds of executive positions compared to program launch. These efficiency gains are critical to the broader financial plan. Net financial debt fell below €30 billion by the end of 2025, helped by €2.1 billion in free cash flow. Management now targets a net debt level of €32 billion by year-end 2026, while maintaining an adjusted operating earnings forecast of €9.4 billion to €9.9 billion for the full year.
Market waits on the gavel
Despite the operational bright spots, the stock remains stuck in a technical downtrend. The €37.74 close Tuesday put it below the 50-day moving average of €38.86, reinforcing the cautious tone. Bayer’s market capitalization stands at roughly €37.73 billion.
Bayer at a turning point? This analysis reveals what investors need to know now.
Analysts see the near-term direction dictated entirely by legal developments. The June 4 opt-out deadline will provide an early reading on how many plaintiffs are willing to accept the settlement terms. The July court hearing and the potential Supreme Court ruling will then cement whether Bayer can finally turn the page on its glyphosate saga. Until then, the gap between operational strength and investor sentiment shows no sign of narrowing.
Ad
Bayer Stock: New Analysis - 26 May
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
